Verge Genomics takes AI-sourced drug for ALS into clinic
pharmaphorum
OCTOBER 31, 2022
Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. Alice Zhang.
DNA Drugs Genome Marketing 
Investment fuels AI-driven development of breakthrough genomic medicines
pharmaphorum
OCTOBER 12, 2022
David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.
Genome 
102
102 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Modernizing cell culture processes for the next wave of genomic medicine
Pharmaceutical Technology
FEBRUARY 3, 2023
The field of genomic medicine has reached a true turning point. As opposed to other therapies or drugs that basically help you manage a condition, gene therapy has the potential to cure a disease,” says Nicole Faust, PhD, General Manager, Cell Line Development, Cytiva. CEVEC became part of Cytiva in October 2022.
Genome 244
244 
UNH team finds repurposed drug hinders enzyme activity linked to Covid-19
Pharmaceutical Technology
JUNE 23, 2022
Researchers at the University of New Hampshire (UNH) have found that a repurposed drug, CCG-50014, could hinder the activity of a key enzyme of the SARS-CoV-2 virus, which causes Covid-19. Utilising a currently available drug compound in a new way is called drug repurposing.
Drugs 130
130 
Spatial Genomics, Transcriptomics and Proteomics Solutions – An Amelioration of Tissue Analytics
Roots Analysis
AUGUST 28, 2022
As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players.
Genome 52
52 
FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review
The Pharma Data
MARCH 7, 2022
Decision Regarding Slick-Haired Cattle is Agency’s First Enforcement Discretion Decision for an Intentional Genomic Alteration in an Animal for Food Use. IGAs are alterations made using molecular technologies that introduce changes to the genome of an animal. Today, the U.S. Solomon, D.V.M., Related Information.
Genome 52
52 
Why Trusted Research Environments are key to the future of genomics
Drug Discovery World
MARCH 27, 2023
Genomics is driving a revolution in drug development and, in the long run, the state of public healthcare. The first draft human genome took a decade to create, and 13 years to complete. Advances in sequencing are leading to scientific breakthroughs in preventative care, faster diagnoses, and proactive medical interventions.
Genome 52
52 
Synthetic biology tools advancing and accelerating drug discovery efforts
Drug Discovery World
NOVEMBER 15, 2022
Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. . It has made its way into almost every aspect of drug discovery, whether it’s exploring basic biology, modelling diseases, identifying and validating targets, or performing drug screens. .
DNA 98
98 
The latest drug discovery product launches
Drug Discovery World
MAY 25, 2023
DNA Script: SYNTAX DNA printing platform Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.
Production 52
52 
Next Generation Sequencing (NGS) Library Preparation Kits Market: Current Scenario and Future Potential
Roots Analysis
FEBRUARY 21, 2022
Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.
Marketing 52
52 
Synthetic biology: Shaping the future of drug discovery
Drug Discovery World
NOVEMBER 14, 2022
Using synthetic DNA to develop drugs and to better understand the toxic effects of them is a key driver for this market. BCC Research reports that the global market for synthetic biology is estimated to increase from $9.5 With reports of the drug being prescribed to President Biden, the drug recently hit the headlines.
Drugs 52
52 
Drug discovery’s latest top-level appointments
Drug Discovery World
APRIL 29, 2024
The last couple of months has seen a number of changes in senior roles in the drug discovery sector. He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021.
Drugs 52
52 
BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test at the Point of Care
The Pharma Data
NOVEMBER 26, 2020
26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. At present, most antibody tests on the market require samples to be sent to a lab for analysis.
DNA 52
52 
How digital innovation is helping therapeutics to get to market faster
Drug Discovery World
FEBRUARY 6, 2024
As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Quris-AI, which combines patient-on-a-chip, AI and real-time nano-sensing technologies to predict the safety and efficacy of drug candidates.
Marketing 69
69 
India: Why is the country ramping up drug discovery research?
Drug Discovery World
AUGUST 8, 2023
DDW’s Megan Thomas takes a deeper look into why India is ramping up drug discovery research, and explores the country’s innovation hubs of interest. In the global pharmaceuticals market, India ranks third worldwide for production by volume and the domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 1.
Research 52
52 
Verve starts trials of cholesterol drug in test of base editing technique
pharmaphorum
JULY 13, 2022
Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment. Through base editing, drugs replace single nucleotide in the DNA strand with another, without making double-strand breaks (DSBs) in the gene.
Gene Editing 98
98 
FoundationOne Liquid CDx Is a New Companion Diagnostic for Metastatic Colorectal Cancer
XTalks
JUNE 16, 2023
Foundation Medicine recently announced that the US Food and Drug Administration (FDA) approved FoundationOne Liquid CDx to serve as a companion diagnostic for identifying metastatic colorectal cancer patients with BRAF V600E alterations, suitable for treatment with Pfizer’s Braftovi (encorafenib) with cetuximab. billion in 2022 to $15.91
FDA Approval 97
97 
Where is the drug discovery expertise happening in the UK?
Drug Discovery World
OCTOBER 16, 2023
The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.
Drugs 75
75 
Life Science Trends to Look Out for in 2024
XTalks
DECEMBER 20, 2023
As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. Regulatory bodies are also taking note of the applications of AI in drug development.
Life Science 119
119 
Can liquid biopsies transform precision medicine?
Drug Discovery World
JANUARY 17, 2024
Challenges in the Oncology Clinical Trials Space The oncology market is a key growth driver for the pharma industry, with global drug revenues expected to reach US$390 billion by 2027 and the annual number of new cancer cases set to grow from 18 to 27 million by 2040 1,2.
Medicine 59
59 
Leading innovators in genetically modified animal models for the pharmaceutical industry
Pharmaceutical Technology
FEBRUARY 15, 2023
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.
Genetics 130
130 
mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends
Roots Analysis
MARCH 16, 2023
Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.
Vaccination 52
52 
AstraZeneca builds its AI capabilities again with Illumina tie-up
pharmaphorum
OCTOBER 12, 2022
AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data generated from “omics” studies.
Genome 62
62 
Oxford Nanopore makes stellar debut on UK stock market
pharmaphorum
OCTOBER 1, 2021
Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 The post Oxford Nanopore makes stellar debut on UK stock market appeared first on. billion) mark.
Marketing 52
52 
NICE rejects prostate cancer drug due to cost of genetic testing
Drug Discovery World
SEPTEMBER 7, 2022
The drug has also been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat some breast cancer patients, though the decision from NICE on this indication is still awaited. NICE has judged olaparib too expensive partly because of the cost of genetic testing to tailor the drug for patients.
Genetics 52
52 
DDW top reads in 2023
Drug Discovery World
DECEMBER 21, 2023
DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. DDW Multimedia Editor Megan Thomas explored three trends in the market.
Gene Therapy 59
59 
The era of precision neuroscience
Drug Discovery World
MARCH 6, 2024
To find new ways of diagnosing and treating complex diseases we first must understand the mechanisms underpinning their key pathological drivers, how these relate to different patient subgroups, and which drugs might be useful in ameliorating their effects – this is the basis of precision neuroscience. This is wholly unsurprising.
Genome 64
64 
Next Generation Sequencing (NGS) Library Preparation Kits: Revolutionizing the Field of Genetic Sciences
Roots Analysis
FEBRUARY 23, 2022
Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. NGS Library Preparation Kits Market. Currently, close to 60 industry players are actively offering NGS kits for preparing DNA / RNA libraries.
Genetics 52
52 
SLAS2024: Day Two Highlights
Drug Discovery World
FEBRUARY 6, 2024
Scientific sessions Tuesday’s presentations spanned a range of topics, including functional genomics for target identification, next-generation proteomics, self-driving laboratories, the future of cell culture, and ‘lab on a particle’ technology. The post SLAS2024: Day Two Highlights appeared first on Drug Discovery World (DDW).
Life Science 64
64 
AZ aims at Pfizer, GSK with potential new PARP cancer drug
pharmaphorum
APRIL 14, 2021
AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer. . The drug has gone on to become a huge success, generating sales of nearly $1.8 All of the approved drugs in the class are hitting PARP2 and this could give AZD5305 an advantage, said O’Connor. “And
Drugs 57
57 
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
The Pharma Data
DECEMBER 14, 2020
”) platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. representing the largest market.
Drugs 52
52 
The microbiome in precision medicine
Drug Discovery World
JULY 26, 2023
With 100-fold the number of genes in the human genome 1 , this microbial collection is a rich genetic signature of clinical significance that we have only recently gained the tools to explore. These novel tools are facilitating the exploration of the microbiome in diagnostics development and drug discovery.
Medicine 52
52 
SLAS2023: We have the building blocks, onto the building
Drug Discovery World
FEBRUARY 13, 2023
In the time that has passed since SLAS2022 in Boston, USA, the drug discovery industry has had to deal with all manner of external obstacles, from the war in Ukraine, to how Brexit has changed the world’s relationship with the UK, and the post-Covid-19 catch-up now that vaccines have rolled out internationally.
Genome 52
52 
Companies unite to advance non-viral CRISPR cell engineering
Drug Discovery World
FEBRUARY 20, 2023
Indee Labs and GenScript have formed a research collaboration with the aim to develop a DNA knock-in kit for Hydropore to enable large transgene inserts above the 5kb limit for AAV. The post Companies unite to advance non-viral CRISPR cell engineering appeared first on Drug Discovery World (DDW).
Engineer 52
52 
Gene editing: beyond the hype
pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. They wanted someone who had lots of experience in drug development, was a molecular biologist, and was stubborn enough to take on CRISPR!” billion in funding.
Gene Editing 145
145 
Advances in cell line development
Drug Discovery World
APRIL 25, 2024
Cell line development is an essential underpinning of the drug development process, enabling teams to test, optimise and manufacture therapeutics at a commercial scale. The market for cell line development is currently rising due to an increased focus by the life sciences sector on biopharmaceuticals and targeted therapies.
Development 59
59 
Biotech goes social: Tips for effective social media marketing
Drug Discovery World
FEBRUARY 21, 2023
Kristina Tatiossian , PhD, founder of Arkitekt Agency, looks at how biotech companies are currently using social media and provides a five-step guide for how to make the most of this ubiquitous marketing tool. Furthermore, marketing teams can tailor the organisation’s following to feature specific demographics.
Marketing 52
52 
Predictive diagnostics: closing the precision medicine gap
Drug Discovery World
OCTOBER 6, 2022
Jarret Glasscock , PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time. . In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations.
Medicine 52
52 
Start-up hopes to boost production of viral vectors for ATMPs
Drug Discovery World
MAY 16, 2023
The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce advanced therapy medicinal products (ATMPs).
Production 52
52 
BioSpace Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More
The Pharma Data
DECEMBER 2, 2020
Food and Drug Administration (FDA) for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen. Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The drug is a small-molecule inhibitor of the S.
Drugs 52
52 
World RNA Day: What impact RNA it had on drug discovery?
Drug Discovery World
AUGUST 1, 2023
The NIH states: “This natural mechanism for sequence-specific gene silencing promises to revolutionise experimental biology and may have important practical applications in functional genomics, therapeutic intervention, agriculture and other areas.” There are many examples of ways in which RNAi is impacting drug discovery.
RNA 52
52 
Top 10 Fastest Growing Biotech Companies in 2023
XTalks
DECEMBER 13, 2023
Moreover, it has submitted global marketing authorization applications for mRNA-1345, a vaccine designed to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD), supported by favorable data from a predefined interim analysis. vaccine, mRNA-1273.815. million and $38.8 million and $33.9
Genetics 111
111 
Comment: LSX World Congress 2023
Drug Discovery World
JUNE 5, 2023
The panel was moderated by Alexander Nuyken, Head Life Sciences Markets Europe, Middle East & Africa, JLL. I consider one of my responsibilities to advocate the advent of a new era for 3D genomics. Our final goal is to pioneer the 3D genomic field and demonstrate the impact on precision medicine.
Genome 52
52 
Guide to using AAV vectors in gene therapy
Drug Discovery World
FEBRUARY 8, 2024
This all creates numerous challenges for the market. These include automated solutions, proprietary genomics protocols, specialists to advise on global cGMP repository and logistics, plus experts to guide researchers through advanced therapy development. Dr O’Hara also provided an AAV plasmid preparation case study.
Gene Therapy 59
59 
Let's personalize your content